Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/30/2025

PCP Prophylaxis in Nephrotic Syndrome

Primary Indication: PCP Prophylaxis

  • The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend prophylactic trimethoprim-sulfamethoxazole for patients with nephrotic syndrome who are receiving high-dose prednisone or other immunosuppressive agents, including rituximab and cyclophosphamide, to prevent Pneumocystis jirovecii pneumonia (PCP) 1, 2
  • The combination of immunosuppressive medications, nephrotic syndrome, uremia, and malnutrition substantially elevates the infection risk in these patients 1

Mechanism of Increased Infection Risk

  • Nephrotic syndrome causes a loss of immunoglobulins through urinary protein loss, leading to disease-related immunosuppression 1
  • Treatment with corticosteroids, rituximab, and cyclophosphamide profoundly suppresses cellular and humoral immunity, further increasing the infection risk 1, 2

Additional Considerations Before Starting Immunosuppression

  • The KDIGO guidelines emphasize the need for a comprehensive infection screening protocol before initiating immunosuppressive therapy in nephrotic syndrome patients, including screening for tuberculosis, hepatitis B and C, HIV, and syphilis 1, 2
  • Patients from endemic tropical regions should be evaluated for Strongyloides, particularly those with eosinophilia and elevated IgE 1, 2
  • Vaccinations, including pneumococcal, influenza, and herpes zoster (Shingrix), should be updated before starting immunosuppression 1, 3

Common Pitfalls to Avoid

  • Failing to prescribe prophylaxis when initiating high-dose corticosteroids or other immunosuppressive agents can result in preventable, life-threatening PCP 1, 2
  • Discontinuing prophylaxis prematurely when immunosuppression is ongoing leaves patients vulnerable to opportunistic infections 1